Gould Robert J 4/A
4/A · Fulcrum Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Fulcrum Therapeutics (FULC) Director Robert J. Gould Sells 15,000 Shares
What Happened
- Robert J. Gould, a director of Fulcrum Therapeutics (FULC), sold 15,000 shares in an open-market transaction on January 2, 2026. The corrected weighted-average price was $10.8726 per share, for aggregate proceeds of approximately $163,089. The shares were sold at prices ranging from $10.60 to $11.33.
Key Details
- Transaction date: 2026-01-02 (reported in this Form 4/A filed 2026-02-04).
- Transaction type/code: Sale (S) — open market.
- Price: Weighted average $10.8726; range $10.60–$11.33 (multiple trades).
- Proceeds: ~$163,089.
- Shares owned after transaction: Not specified in the information provided.
- Footnotes: Sale was effected under a Rule 10b5-1 trading plan adopted August 1, 2025. This is an amended Form 4 correcting the weighted-average price from $11.8726 to $10.8726.
- Timeliness: Original Form 4 was submitted earlier (noted as Jan 6, 2026); this amendment corrects pricing details.
Context
- This was a sale executed under a 10b5-1 plan, which indicates a pre-arranged trading program rather than ad-hoc trading; such sales are often routine and do not necessarily signal a change in the insider’s view of the company. For retail investors, purchases generally carry clearer bullish signals than routine pre-planned sales.
Insider Transaction Report
Form 4/AAmended
Gould Robert J
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-01-02$10.87/sh−15,000$163,089→ 469,864 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. This Form 4/A corrects the weighted average price indicated in the Form 4 submitted on January 6, 2026 from $11.8726 to $10.8726.
Signature
/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould|2026-02-04